JP2008504551A - アルツハイマー病のバイオマーカー - Google Patents
アルツハイマー病のバイオマーカー Download PDFInfo
- Publication number
- JP2008504551A JP2008504551A JP2007518700A JP2007518700A JP2008504551A JP 2008504551 A JP2008504551 A JP 2008504551A JP 2007518700 A JP2007518700 A JP 2007518700A JP 2007518700 A JP2007518700 A JP 2007518700A JP 2008504551 A JP2008504551 A JP 2008504551A
- Authority
- JP
- Japan
- Prior art keywords
- gsk
- disease
- antibody
- alzheimer
- inactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 68
- 239000000090 biomarker Substances 0.000 title description 6
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000012360 testing method Methods 0.000 claims abstract description 17
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 11
- 208000027061 mild cognitive impairment Diseases 0.000 claims abstract description 10
- 210000001124 body fluid Anatomy 0.000 claims abstract description 3
- 239000010839 body fluid Substances 0.000 claims abstract description 3
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims abstract 15
- 230000000694 effects Effects 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 102000001267 GSK3 Human genes 0.000 description 48
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 102000013498 tau Proteins Human genes 0.000 description 10
- 108010026424 tau Proteins Proteins 0.000 description 10
- 206010012289 Dementia Diseases 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 7
- 239000003550 marker Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical class C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 3
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 3
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 3
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 208000024466 platelet membrane fluidity Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0414894.6A GB0414894D0 (en) | 2004-07-02 | 2004-07-02 | Biomarkers of alzheimer's disease |
| PCT/GB2005/002592 WO2006003414A2 (en) | 2004-07-02 | 2005-07-01 | Biomarkers of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504551A true JP2008504551A (ja) | 2008-02-14 |
| JP2008504551A5 JP2008504551A5 (enExample) | 2008-08-21 |
Family
ID=32843494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518700A Withdrawn JP2008504551A (ja) | 2004-07-02 | 2005-07-01 | アルツハイマー病のバイオマーカー |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080076140A1 (enExample) |
| EP (1) | EP1763674A2 (enExample) |
| JP (1) | JP2008504551A (enExample) |
| CN (1) | CN101010589A (enExample) |
| AU (1) | AU2005258926A1 (enExample) |
| BR (1) | BRPI0512948A (enExample) |
| CA (1) | CA2571692A1 (enExample) |
| GB (1) | GB0414894D0 (enExample) |
| WO (1) | WO2006003414A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010210610A (ja) * | 2008-12-17 | 2010-09-24 | National Tsinghua Univ | 病的細胞の検出及びその利用 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007138408A1 (en) | 2006-05-25 | 2007-12-06 | Ge Healthcare Limited | 11c/18 f-labeled inhibitors of glycogen synthase kinase-3 |
| WO2009074331A2 (en) * | 2007-12-11 | 2009-06-18 | Julius-Maximilians-Universität Würzburg | Early and differential diagnosis test for alzheimer's disease |
| EP2279420B1 (en) | 2008-03-21 | 2014-01-29 | Manuela G. Neuman | METHODS FOR THE DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE VERSUS FRONTOTEMPORAL DEMENTIA, COMPRISING FAS-L, TNF-alpha AND ccCK-18 AS BIOMARKERS |
| US20120040361A1 (en) * | 2010-07-22 | 2012-02-16 | National Tsing Hua University | Methods and compositions for detection of lethal system and uses thereof |
| CN104237526B (zh) * | 2013-06-18 | 2016-08-17 | 磁量生技股份有限公司 | 一种检测阿兹海默症罹患风险的系统 |
| US20170102398A1 (en) * | 2014-03-05 | 2017-04-13 | Humanetics Corporation | Predicting and reducing cognitive decline based on gsk-3 levels |
| CN104698188A (zh) * | 2015-03-04 | 2015-06-10 | 华中科技大学 | 检测人血小板GSK-3β蛋白活性的斑点印迹方法 |
| CN111323597A (zh) * | 2018-12-14 | 2020-06-23 | 陈志成 | 用于检测受试者中mci和/或ad的方法、试剂盒及筛选化合物的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005240669A1 (en) * | 2004-05-07 | 2005-11-17 | Garvan Institute Of Medical Research | Detecting disease association with aberrant glycogen synthase kinase 3-beta expression |
-
2004
- 2004-07-02 GB GBGB0414894.6A patent/GB0414894D0/en not_active Ceased
-
2005
- 2005-07-01 US US11/630,769 patent/US20080076140A1/en not_active Abandoned
- 2005-07-01 CN CNA2005800225150A patent/CN101010589A/zh active Pending
- 2005-07-01 EP EP05756942A patent/EP1763674A2/en not_active Withdrawn
- 2005-07-01 JP JP2007518700A patent/JP2008504551A/ja not_active Withdrawn
- 2005-07-01 WO PCT/GB2005/002592 patent/WO2006003414A2/en not_active Ceased
- 2005-07-01 BR BRPI0512948-6A patent/BRPI0512948A/pt not_active Application Discontinuation
- 2005-07-01 CA CA002571692A patent/CA2571692A1/en not_active Abandoned
- 2005-07-01 AU AU2005258926A patent/AU2005258926A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010210610A (ja) * | 2008-12-17 | 2010-09-24 | National Tsinghua Univ | 病的細胞の検出及びその利用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101010589A (zh) | 2007-08-01 |
| WO2006003414A3 (en) | 2006-03-16 |
| BRPI0512948A (pt) | 2008-04-15 |
| AU2005258926A1 (en) | 2006-01-12 |
| CA2571692A1 (en) | 2006-01-12 |
| GB0414894D0 (en) | 2004-08-04 |
| US20080076140A1 (en) | 2008-03-27 |
| WO2006003414A2 (en) | 2006-01-12 |
| EP1763674A2 (en) | 2007-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ding et al. | Loss of capillary pericytes and the blood–brain barrier in white matter in poststroke and vascular dementias and Alzheimer’s disease | |
| Lehmann et al. | Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals | |
| Bongianni et al. | Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease | |
| Akhtar et al. | Measurements of auto‐antibodies to α‐synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease | |
| Miyajima et al. | Soluble amyloid precursor protein α in the cerebrospinal fluid as a diagnostic and prognostic biomarker for idiopathic normal pressure hydrocephalus | |
| Montine et al. | Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer’s disease as identified by biomarkers | |
| Chalbot et al. | Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease | |
| Ibach et al. | Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample | |
| Eller et al. | α-Synuclein in Parkinson disease and other neurodegenerative disorders | |
| Bartosik‐Psujek et al. | Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone | |
| Kiđemet‐Piskač et al. | Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia | |
| CN106461677B (zh) | 肺高血压病的检查方法 | |
| Liang et al. | Salivary biological biomarkers for Alzheimer’s disease | |
| MX2014012306A (es) | Biomarcadores salivales especificos para deteccion de riesgo, diagnostico temprano, pronostico y vigilancia de las enfermedades de alzheimer y de parkinson. | |
| CN102933966A (zh) | 阿尔茨海默病的新型诊断制剂 | |
| Youn et al. | Urine neural thread protein measurements in Alzheimer disease | |
| Liu et al. | Periphery biomarkers for objective diagnosis of cognitive decline in type 2 diabetes patients | |
| Mukaetova-Ladinska et al. | Cerebrospinal fluid biomarkers for dementia with lewy bodies | |
| JP2008504551A (ja) | アルツハイマー病のバイオマーカー | |
| Kac et al. | Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease | |
| Rosano et al. | Sex differences in Alzheimer's disease blood biomarkers in a Caribbean population of African ancestry: the Tobago Health Study | |
| JP5914480B2 (ja) | 神経変性疾患の診断方法 | |
| US20240142471A1 (en) | Test for mild cognitive impairment | |
| Catalán-García et al. | BACE-1, PS-1 and sAPPβ levels are increased in plasma from sporadic inclusion body myositis patients: surrogate biomarkers among inflammatory myopathies | |
| McGettigan et al. | The emerging role of blood biomarkers in diagnosis and treatment of Alzheimer’s disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080626 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080626 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100610 |